이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Diagnosis of ECMO Cannula Infection: Prospective Comparison of Sampling Methods (ECMO-CSI-DIAG)

2026년 11월 4일 업데이트: Assistance Publique - Hôpitaux de Paris

Diagnosis of ECMO Cannula Infection: a Prospective Comparison of Sampling Methods

Extracorporeal membrane oxygenation (ECMO) is increasingly used as rescue support in patients with refractory respiratory and/or circulatory failure. ECMO cannula site infection (ECMO-CSI) complicates approximately 10% of ECMO runs and is associated with septic shock, prolonged intensive care unit (ICU) stay and increased mortality. To date, there is neither a standardized definition nor consensus diagnostic criteria for ECMO-CSI, and the optimal microbiological sampling strategy, as well as the diagnostic accuracy of the available methods, remains undetermined.

This single-center, prospective, non-interventional study aims to compare the diagnostic accuracy of three microbiological sampling methods (superficial swab of the cannula insertion site, needle aspiration along the cannula tract, and cannula tip culture) for the diagnosis of ECMO-CSI in adult patients receiving veno-venous or veno-arterial ECMO.

A superficial swab and a needle aspirate will be obtained at each cannulation site on the day ECMO-CSI is clinically suspected and on the day of decannulation. In addition, the tip of each cannula will be cultured at decannulation. The results of these index tests will be compared with a reference diagnosis of ECMO-CSI established by an adjudication committee of expert clinicians blinded to the index test results.

A total of 500 patients will be enrolled in order to obtain at least 50 patients with adjudicated ECMO-CSI.

연구 개요

상태

아직 모집하지 않음

상세 설명

BACKGROUND ECMO is a life-support technique widely used in refractory respiratory and/or circulatory failure. It is associated with infectious complications, notably cannula infections, whose incidence is estimated at about 10%. These infections are associated with an increased risk of septic shock and contribute to longer ICU stay and higher mortality. There is to date neither a standardized definition nor consensus diagnostic criteria, particularly regarding the nature and diagnostic performance of the microbiological samples to be collected. Superficial swabbing of the insertion site is simple and minimally invasive but frequently yields contaminated results or results reflecting colonizing flora. More invasive methods (needle aspiration, culture of the cannula tip at decannulation) may be more specific but are less commonly performed and have not been comparatively validated. A recent international Delphi consensus identified cannula aspiration and cannula swab as the two preferred microbiological methods. The lack of an established diagnostic algorithm leads to heterogeneous management, with potential consequences for antibiotic stewardship and patient outcomes.

DESIGN Single-center, prospective, non-interventional study conducted in the medical ICU of Pitié-Salpêtrière Hospital (AP-HP, Paris, France), which manages about 300 ECMO patients per year. All adult patients on veno-venous or veno-arterial ECMO are eligible. The patient (or trusted person, relative or legal representative) is informed and the patient is included unless an objection is expressed. Inclusion period: 24 months. Participation: duration of ICU stay (maximum 2 months). Total study duration: 26 months.

SAMPLING

  • Swab (performed for the research): a sterile single-use swab is applied to the cannula insertion orifice.
  • Needle aspiration (standard of care): 1 mL of sterile saline is injected along the cannula through a syringe and a plastic catheter, re-aspirated and transferred to a sterile container.
  • Cannula tip (standard of care): at decannulation, the distal 5 cm of the cannula is cut with a sterile blade and placed in a sterile container.

On the day the clinician in charge suspects a cannulation site infection, a swab and a needle aspiration are performed at each cannulation site. On the day of decannulation, a swab and a needle aspiration are performed at each cannulation site and the tip of each cannula is sent for culture.

MICROBIOLOGY Samples are cultured in the microbiology laboratory using the Brun-Buisson technique: suspension in 1 mL of sterile saline and vortexing for about 1 minute, then 100 microliters are plated on fresh blood agar, chocolate agar and Sabouraud agar, incubated for 48 hours to 10 days under aerobic and anaerobic conditions and read daily. In case of positive culture, identification is performed by mass spectrometry (MALDI-TOF). Each sample is recorded as culture positive or culture negative.

REFERENCE STANDARD The reference diagnosis of ECMO cannula infection is the clinical diagnosis established by an adjudication committee of three clinician experts, ruling retrospectively and blinded to the results of the index tests, on the basis of the available clinical, biological, microbiological and outcome data.

DATA Data are collected prospectively from the electronic medical record into a REDCap electronic case report form hosted by AP-HP. At each sampling: local appearance of the insertion site (photograph), general and hemodynamic status, biological inflammatory markers, nosocomial infection during the stay, antibiotic therapy within the previous 7 days, rectal colonization with a multidrug-resistant organism, positive blood culture within the previous 48 to 72 hours, duration of ECMO support.

STATISTICS The sample size was set to obtain at least 50 cases of cannula infection; with an expected incidence of 10%, 500 patients will be included. Sensitivity, specificity and predictive values of each sampling strategy are computed against the reference diagnosis. Paired comparisons use the McNemar test. Agreement between methods is assessed with the kappa coefficient. Exploratory logistic regression analyses will identify factors associated with microbiological positivity. Analyses are performed on complete cases; a failed sampling technique is considered negative.

연구 유형

관찰

등록 (추정된)

500

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

      • Paris, 프랑스
        • Hôpital Pitié Salpêtrière, Service de médecine intensive et réanimation
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Charles Edouard LUYT, MD, PhD

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

Adult patients managed in the medical intensive care unit of Pitié-Salpêtrière Hospital (Paris, France) on veno-venous or veno-arterial ECMO during the inclusion period.

설명

Inclusion Criteria:

  • Age >= 18 years
  • Patient admitted to the intensive care unit with veno-venous or veno-arterial ECMO

Exclusion Criteria:

  • Pregnant women
  • Persons deprived of liberty
  • Sample collection impossible for technical reasons
  • Patients on central ECMO

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
Adult patients on ECMO

Adult patients on veno-venous or veno-arterial ECMO in the ICU. Swab and needle aspiration of each cannulation site on the day of clinical suspicion of cannula infection and on the day of decannulation; culture of each cannula tip at decannulation.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Diagnostic performance of each sampling strategy (superficial swab, needle aspiration, cannula tip culture) for the diagnosis of ECMO cannula infection
기간: On the day of clinical suspicion of cannula infection and on the day of decannulation, up to ICU discharge (maximum 2 months)

Sensitivity, specificity, positive and negative predictive values of each sampling strategy, and its agreement with the reference diagnosis of cannula infection established by the adjudication committee.

On the day of clinical suspicion of cannula infection and on the day of decannulation, up to ICU discharge (maximum 2 months)

2차 결과 측정

결과 측정
측정값 설명
기간
Factors associated with positivity of the microbiological samples
기간: On the day of clinical suspicion of cannula infection and on the day of decannulation, up to ICU discharge (maximum 2 months)

Variables assessed at each sampling: weight (kg); height (meters), BMI (kg/m2), local appearance of the cannula insertion site on a photograph (purulence, inflammatory signs), fever (temperature (°C), systolic blood pressure (mmHg), diastolic blood pressure (mmHg), heart rate (bpm), noradrenaline (µg/kg/min), dobutamine (µg/kg/min)), biological criteria: hemoglobin (g/dL), white blood cell count (G/L), CRP (mg/L), PCT (ng/l), pH, bicarbonates (mmol/L), arterial lactate (mmol/L), nosocomial infection during the stay, antibiotic therapy within 7 days before sampling, rectal colonization with a multidrug-resistant organism, positive blood culture within 48 to 72 hours before sampling, positive culture of the ECMO cannula tip, duration of ECMO support.

On the day of clinical suspicion of cannula infection and on the day of decannulation, up to ICU discharge (maximum 2 months)
Agreement between the sampling methods
기간: On the day of clinical suspicion of cannula infection and on the day of decannulation, up to ICU discharge (maximum 2 months)

Agreement on culture positivity and on microbiological identification between swab, needle aspiration and cannula tip culture (kappa coefficient).

On the day of clinical suspicion of cannula infection and on the day of decannulation, up to ICU discharge (maximum 2 months)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Charles Edouard LUYT, MD, PhD, Assistance Publique - Hôpitaux de Paris

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 11월 1일

기본 완료 (추정된)

2029년 1월 1일

연구 완료 (추정된)

2029년 1월 1일

연구 등록 날짜

최초 제출

2026년 10월 19일

QC 기준을 충족하는 최초 제출

2026년 10월 19일

처음 게시됨 (실제)

2026년 10월 26일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 6일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 4일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다